Survival after transfusion as assessed in a large multistate US cohort

被引:42
作者
Kleinman, S
Marshall, D
AuBuchon, J
Patton, M
机构
[1] Kleinman Biomed Res, Victoria, BC V9A 4W4, Canada
[2] Innovus Res Inc, Burlington, ON, Canada
[3] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[4] Constella Hlth Strategies, Herndon, VA USA
关键词
D O I
10.1111/j.1537-2995.2003.00660.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The only survival and mortality data on a general population of transfused patients in the United States is more than two decades old. More contemporary data are needed to reflect more current patient populations and transfusion practices. STUDY DESIGN AND METHODS: Data were extracted from Constella Health Strategies Sciences' managed-care administrative claims database that contains private health care claims. Patients were selected if they had at least one professional or facility claim indicating transfusion in 1995. Only the first transfusion in the time period was included so that each patient was counted only once and all claims were unduplicated. Survival for five years after transfusion was the primary outcome measure. RESULTS: A total of 6779 patients were included in the analysis. A total of 4658 (69%) patients were alive 1 year after transfusion, 4056 (60%) were alive at 2 years, and 3092 (46%) were alive 5 years after transfusion. Overall annual mortality was 31 percent in Year 1 after transfusion, 14 percent in Year 2, and 10 percent in each of Years 3 through 5. Transfusion mortality was much higher in recipients older than age 65 at the time of transfusion, who comprised 60 percent of transfused patients. CONCLUSION: These data from the mid 1990s can be used in models of the effectiveness of risk reduction interventions and in models of the disease consequences of infections transmitted through blood transfusions.
引用
收藏
页码:386 / 390
页数:5
相关论文
共 14 条
[1]   Medical progress - Transfusion medicine (First of two parts) - Blood transfusion [J].
Goodnough, LT ;
Brecher, ME ;
Kanter, MH ;
AuBuchon, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (06) :438-447
[2]   Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States [J].
Marshall, DA ;
Kleinman, SH ;
Wong, JB ;
AuBuchon, JP ;
Grima, DT ;
Kulin, NA ;
Weinstein, MC .
VOX SANGUINIS, 2004, 86 (01) :28-40
[3]   Blood transfusion in a random sample of hospitals in France [J].
Mathoulin-Pélissier, S ;
Salmi, LR ;
Verret, C ;
Demoures, B .
TRANSFUSION, 2000, 40 (09) :1140-1146
[4]   HCV lookback in the United States: effectiveness of an extended lookback program [J].
Menozzi, D ;
Udulutch, T ;
Llosa, AE ;
Galel, SA .
TRANSFUSION, 2000, 40 (11) :1393-1398
[5]  
TITLESTAD K, 2003, VOX SANG S2, V83, P220
[6]   Long-term survival in transfusion recipients in Sweden, 1993 [J].
Tynell, E ;
Norda, R ;
Shanwell, A ;
Björkman, A .
TRANSFUSION, 2001, 41 (02) :251-255
[7]   LONG-TERM SURVIVAL AFTER BLOOD-TRANSFUSION [J].
VAMVAKAS, EC ;
TASWELL, HF .
TRANSFUSION, 1994, 34 (06) :471-477
[8]   Ten-year survival of transfusion recipients identified by hepatitis C lookback [J].
Vamvakas, EC .
TRANSFUSION, 2003, 43 (03) :418-418
[9]   Four-year survival of transfusion recipients identified by hepatitis C lookback [J].
Vamvakas, EC ;
Goldstein, R .
TRANSFUSION, 2002, 42 (06) :691-697
[10]   Length of survival after perioperative transfusion [J].
Vamvakas, EC ;
Moore, SB .
TRANSFUSION MEDICINE, 1997, 7 (02) :115-121